A new invited review article has been published entitled “Antiviral therapeutic approaches for human rhinovirus infections” in the journal Future Virology. The review, authored by Dr Victor Casanova, Filipa Henderson Sousa, Dr Craig Stevens and Dr Peter Barlow, highlights the current, limited therapeutic options for treating human Rhinovirus. This virus is the primary cause of the common cold and cause dangerous disease exacerbations in individuals with lung conditions such as asthma, COPD and Cystic Fibrosis.
The article highlights some recent work, particularly in the area of small molecule inhibitors, that have been shown to have antiviral activity against rhinovirus. It also highlights the recent work by Sousa et al. (2017) demonstrating that cathelicidins from human and other mammals have highly effective activity against Rhinovirus.
Peter also wrote an article for The Conversation to accompany the review, which attracted media coverage from The Scotsman (1) (2) and The Express among others.
The full text of the review article can be found on the journal website.
A look behind the writing of the article can be found here on ID-Hub
